BIOMAT Database Logo BIOMAT Database Logo

Levodopa-induced breathing, cognitive and behavioral changes in Parkinson's disease. 2011

Nicola Tambasco, and Vincenzo Belcastro, and Antongiulio Gallina, and Anna Castrioto, and Paolo Calabresi, and Aroldo Rossi

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D012120 Respiration Disorders Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available. Disorder, Respiration,Disorders, Respiration,Respiration Disorder
D002230 Carbidopa An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself. Methyldopahydrazine,Carbidopa, (R)-Isomer,Carbidopa, (S)-Isomer,Lodosin,Lodosyn,MK-485,MK-486,MK 485,MK 486,MK485,MK486
D003072 Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment. Overinclusion,Disorder, Cognition,Disorders, Cognition
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000978 Antiparkinson Agents Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson

Related Publications

Nicola Tambasco, and Vincenzo Belcastro, and Antongiulio Gallina, and Anna Castrioto, and Paolo Calabresi, and Aroldo Rossi
[Levodopa and cognitive disorders in Parkinson's disease].
January 2006, Revista de neurologia,
Nicola Tambasco, and Vincenzo Belcastro, and Antongiulio Gallina, and Anna Castrioto, and Paolo Calabresi, and Aroldo Rossi
Levodopa-responsive breathing discomfort in Parkinson's disease patients.
July 2018, Journal of neural transmission (Vienna, Austria : 1996),
Nicola Tambasco, and Vincenzo Belcastro, and Antongiulio Gallina, and Anna Castrioto, and Paolo Calabresi, and Aroldo Rossi
Early cognitive changes and nondementing behavioral abnormalities in Parkinson's disease.
January 2005, Advances in neurology,
Nicola Tambasco, and Vincenzo Belcastro, and Antongiulio Gallina, and Anna Castrioto, and Paolo Calabresi, and Aroldo Rossi
Early cognitive changes and nondementing behavioral abnormalities in Parkinson's disease.
January 1995, Advances in neurology,
Nicola Tambasco, and Vincenzo Belcastro, and Antongiulio Gallina, and Anna Castrioto, and Paolo Calabresi, and Aroldo Rossi
Apomorphine induced cognitive changes in Parkinson's disease.
August 1994, Journal of neurology, neurosurgery, and psychiatry,
Nicola Tambasco, and Vincenzo Belcastro, and Antongiulio Gallina, and Anna Castrioto, and Paolo Calabresi, and Aroldo Rossi
Levodopa-induced dyskinesia in Parkinson's disease.
March 2005, Journal of neural transmission (Vienna, Austria : 1996),
Nicola Tambasco, and Vincenzo Belcastro, and Antongiulio Gallina, and Anna Castrioto, and Paolo Calabresi, and Aroldo Rossi
Levodopa-induced dyskinesias in Parkinson's disease.
January 2007, Handbook of clinical neurology,
Nicola Tambasco, and Vincenzo Belcastro, and Antongiulio Gallina, and Anna Castrioto, and Paolo Calabresi, and Aroldo Rossi
Levodopa-induced hyperhomocysteinaemia in Parkinson's disease.
July 2003, Acta neurologica Scandinavica,
Nicola Tambasco, and Vincenzo Belcastro, and Antongiulio Gallina, and Anna Castrioto, and Paolo Calabresi, and Aroldo Rossi
Aberrations in temporal dynamics of cognitive processing induced by Parkinson's disease and Levodopa.
November 2023, Scientific reports,
Nicola Tambasco, and Vincenzo Belcastro, and Antongiulio Gallina, and Anna Castrioto, and Paolo Calabresi, and Aroldo Rossi
Pallidal Structural Changes Related to Levodopa-induced Dyskinesia in Parkinson's Disease.
January 2022, Frontiers in aging neuroscience,
Copied contents to your clipboard!